396 related articles for article (PubMed ID: 25721488)
1. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
Takashita E; Meijer A; Lackenby A; Gubareva L; Rebelo-de-Andrade H; Besselaar T; Fry A; Gregory V; Leang SK; Huang W; Lo J; Pereyaslov D; Siqueira MM; Wang D; Mak GC; Zhang W; Daniels RS; Hurt AC; Tashiro M
Antiviral Res; 2015 May; 117():27-38. PubMed ID: 25721488
[TBL] [Abstract][Full Text] [Related]
2. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.
Gubareva LV; Besselaar TG; Daniels RS; Fry A; Gregory V; Huang W; Hurt AC; Jorquera PA; Lackenby A; Leang SK; Lo J; Pereyaslov D; Rebelo-de-Andrade H; Siqueira MM; Takashita E; Odagiri T; Wang D; Zhang W; Meijer A
Antiviral Res; 2017 Oct; 146():12-20. PubMed ID: 28802866
[TBL] [Abstract][Full Text] [Related]
3. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.
Meijer A; Rebelo-de-Andrade H; Correia V; Besselaar T; Drager-Dayal R; Fry A; Gregory V; Gubareva L; Kageyama T; Lackenby A; Lo J; Odagiri T; Pereyaslov D; Siqueira MM; Takashita E; Tashiro M; Wang D; Wong S; Zhang W; Daniels RS; Hurt AC
Antiviral Res; 2014 Oct; 110():31-41. PubMed ID: 25043638
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.
Okomo-Adhiambo M; Sleeman K; Lysén C; Nguyen HT; Xu X; Li Y; Klimov AI; Gubareva LV
Influenza Other Respir Viruses; 2013 Sep; 7(5):645-58. PubMed ID: 23575174
[TBL] [Abstract][Full Text] [Related]
5. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
[TBL] [Abstract][Full Text] [Related]
6. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.
Tamura D; Nguyen HT; Sleeman K; Levine M; Mishin VP; Yang H; Guo Z; Okomo-Adhiambo M; Xu X; Stevens J; Gubareva LV
Antimicrob Agents Chemother; 2013 Dec; 57(12):6141-6. PubMed ID: 24080660
[TBL] [Abstract][Full Text] [Related]
7. In vitro neuraminidase inhibitory concentration (IC
Ikematsu H; Kawai N; Tani N; Chong Y; Bando T; Iwaki N; Kashiwagi S
J Infect Chemother; 2020 Aug; 26(8):775-779. PubMed ID: 32249161
[TBL] [Abstract][Full Text] [Related]
8. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of the influenza virus circulating in the Japanese 2013-2014 season.
Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
J Infect Chemother; 2015 Sep; 21(9):634-8. PubMed ID: 26096495
[TBL] [Abstract][Full Text] [Related]
9. Neuraminidase inhibitor susceptibility profile of human influenza viruses during the 2016-2017 influenza season in Mainland China.
Huang W; Cheng Y; Li X; Tan M; Wei H; Zhao X; Xiao N; Dong J; Wang D
J Infect Chemother; 2018 Sep; 24(9):729-733. PubMed ID: 29866491
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Gubareva LV; Trujillo AA; Okomo-Adhiambo M; Mishin VP; Deyde VM; Sleeman K; Nguyen HT; Sheu TG; Garten RJ; Shaw MW; Fry AM; Klimov AI
Antivir Ther; 2010; 15(8):1151-9. PubMed ID: 21149922
[TBL] [Abstract][Full Text] [Related]
11. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
Samson M; Abed Y; Desrochers FM; Hamilton S; Luttick A; Tucker SP; Pryor MJ; Boivin G
Antimicrob Agents Chemother; 2014 Sep; 58(9):5220-8. PubMed ID: 24957832
[TBL] [Abstract][Full Text] [Related]
12. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.
Takashita E; Daniels RS; Fujisaki S; Gregory V; Gubareva LV; Huang W; Hurt AC; Lackenby A; Nguyen HT; Pereyaslov D; Roe M; Samaan M; Subbarao K; Tse H; Wang D; Yen HL; Zhang W; Meijer A
Antiviral Res; 2020 Mar; 175():104718. PubMed ID: 32004620
[TBL] [Abstract][Full Text] [Related]
13. In vitro neuraminidase inhibitory activities of four neuraminidase inhibitors against influenza viruses isolated in the 2010-2011 season in Japan.
Ikematsu H; Kawai N; Kashiwagi S
J Infect Chemother; 2012 Aug; 18(4):529-33. PubMed ID: 22370919
[TBL] [Abstract][Full Text] [Related]
14. Characterization of neuraminidase inhibitor-resistant influenza A(H1N1)pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in Japan.
Takashita E; Fujisaki S; Kishida N; Xu H; Imai M; Tashiro M; Odagiri T;
Influenza Other Respir Viruses; 2013 Nov; 7(6):1390-9. PubMed ID: 23745712
[TBL] [Abstract][Full Text] [Related]
15. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.
McKimm-Breschkin JL
Influenza Other Respir Viruses; 2013 Jan; 7 Suppl 1(Suppl 1):25-36. PubMed ID: 23279894
[TBL] [Abstract][Full Text] [Related]
16. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.
Monto AS; McKimm-Breschkin JL; Macken C; Hampson AW; Hay A; Klimov A; Tashiro M; Webster RG; Aymard M; Hayden FG; Zambon M
Antimicrob Agents Chemother; 2006 Jul; 50(7):2395-402. PubMed ID: 16801417
[TBL] [Abstract][Full Text] [Related]
17. Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.
Fage C; Tu V; Carbonneau J; Abed Y; Boivin G
Antivir Ther; 2017; 22(8):711-716. PubMed ID: 29082897
[TBL] [Abstract][Full Text] [Related]
18. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.
Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
J Infect Chemother; 2015 Jan; 21(1):39-42. PubMed ID: 25277670
[TBL] [Abstract][Full Text] [Related]
19. Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
Baranovich T; Bahl J; Marathe BM; Culhane M; Stigger-Rosser E; Darnell D; Kaplan BS; Lowe JF; Webby RJ; Govorkova EA
Antiviral Res; 2015 May; 117():10-9. PubMed ID: 25701593
[TBL] [Abstract][Full Text] [Related]
20. Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.
Brown SK; Tseng YY; Aziz A; Baz M; Barr IG
Antiviral Res; 2022 Apr; 200():105280. PubMed ID: 35304163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
